Microorganism for treatment or prevention of corpulence and diabetes mellitus, and pharmaceutical composition containing the same

Abstract

The present invention relates to microorganisms for the treatment or the prevention of obesity or diabetes mellitus, which reduce the amount of monosaccharide or disaccharide which may be absorbed into human body by converting monosaccharides such as glucose, fructose, galactose et al. and disaccharides into polymeric materials which cannot be absorbed by the intestine, and relates to a pharmaceutical composition containing the said microorganisms.

Description

FIELD OF THE INVENTION [0001] The present invention relates to microorganisms for preventing or treating obesity or diabetes mellitus, which are capable of reducing an amount of monosaccharides or disaccharides that can be absorbed into the intestine by converting those mono or disaccharides into polymeric materials that cannot be absorbed in the intestines. The present invention also relates to use of the microorganisms for preventing or treating obesity or diabetes mellitus and a pharmaceutical composition containing the microorganisms. BACKGROUND OF THE INVENTION [0002] Obesity is well known as a chronic disease caused by various factors whose origins have not yet been clearly discovered. It is understood that obesity induces hypertension, diabetes mellitus, coronary heart disease, gall bladder disease, osteoarthritis, sleep apnea, respiratory disorder, endomerial, prostate, breast and colon cancer and the like. [0003] According to the NIH Report (THE EVIDENCE REPORT: Clinical Gu...

AI Technical Summary

Benefits of technology

[0033] Therefore, the object of the present invention is to provide microorganisms capable of living within the intestines and converting oligosaccharides produced by the digestive enzymes into non-digestable polysaccharides, and thereby remarkably reducing the amount of oligosaccharide absorbed into the intestines.

[0034] Another object of the present invention is to provide a pharmaceutical composition comprising at least one of said microorganisms in an amount effective to prevent or treat obesity and diabetes mellitus and a pharmaceutically acceptable carrier. Another object of the present invention is to provide a method for preventing or treating obesity, diabetes mellitus comprising administering to a subject in need thereof capable of pharmaceutical comprising a method for reducing weight gain, controlling blood glucose level and control absorption of blood lipod.

[0038] In addition, the pharmaceutical composition of the present invention may further comprises lubricants, moisturizer, emulsifier, suspension stabilizer, preservative, sweetener and flavor. The pharmaceutical composition of the present invention may be in a form of an enteric coating formulation produced by various methods which have been publicly known, in order to deliver the active ingredients of the pharmaceutical composition, i.e., microorganisms, to the small intestines without degradation by gastric juices in stomach.

[0055] In case of taking the composition of the present invention periodically, microorganisms form colony within the intestines and interrupt absorption of oligosaccharide in the body competitively. Also, non-digestable fibers produced by microorganisms make a healthy condition for other useful microorganisms within the intestines and stimulate the intestinal activity. Consequently, the composition of the present invention functions to treat and prevent obesity and diabetes mellitus.

Problems solved by technology

Diabetes mellitus is one of the most widespread chronic diseases in the world, which impose a substantial expense on the public as well as on patients of diabetes mellitus and their families.

Failure to treat NIDDM, resulting in losing control of blood glucose levels, leads to death of patients from diseases such as atherosclerosis, and / or may cause late complications of diabetes, such as retinopathy, nephropathy or neuropathy.

However, diet-exercise therapy alone or even combined with chemotherapy using such compounds fails to control hyperglycemia in some of the diabetes mellitus patients.

Administration of insulin is very expensive and painful to patients, and furthermore, may cause various detrimental results and various complications in patients.

Diet-exercise therapy involves a low-calorie and low-fat diet accompanying aerobic exercise, but this therapy requiring a regular performance is hard to continue until achieving the goal.

Despite of instant effects, a surgery for physically removing body fat has limitations due to the risk and cost involved in a surgical operation and insufficient durability of the effects.

Although sulfonylurea stimulates insulin-secretion from β-cells in the pancreas, it may accompany side effects, such as hypoglycemia resulting from lowering blood glucose levels under normal levels.

However, it suffers from side effects, such as, nausea, vomiting and diarrhea.

It, however, accompanies undersirable inhibition of absorption of fat-soluble vitamin and may also cause breast cancer.

However, dexfenfluororamine and fenfluoroamine have side effects of nerve toxicity and valvular heart disease.

Also, sibutramine has side effects of increasing heart rate and blood pressure.

However, taking a large amount of these may induce diarrhea.

However, such method also involves problems in requiring facility and manpower for the production of dietary fiber with low productivity.

However, such materials also cause severe side effects.

For example, dextran may induce excessive bleeding by delaying a blood coagulation time.

As mentioned above, although there have been various researches and efforts to develop drugs for treatment or prevention of obesity and diabetes mellitus, their results were not satisfactory.

Various chemical substances mentioned above, have been developed for treatment of obesity and diabetes mellitus, but still suffer from various side effects.

Images